Rhythm Pharmaceuticals Inc (RYTM) Stock Price, Quote & News

Company Profile

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 264 4280

Fax: 857 264 4299

Website: rhythmtx.com

Address:

222 Berkeley Street, 12th Floor, Boston, United States

Stonky_Mcprofitface Apr. 3 at 1:02 PM

$RYTM oh ok.

1 · Reply

Hognose Apr. 2 at 6:26 AM

$RYTM buyout candidate. About to get cheaper. Pickup in the 70s

1 · Reply

abcdzepeda Apr. 2 at 12:50 AM

$RYTM wow, we are trending right now!

1 · Reply

Tech442 Apr. 2 at 12:43 AM

$RYTM

0 · Reply

SportTrade Apr. 2 at 12:32 AM

$PTN $RYTM $ALT $VKTX Palatin is approaching a major value creating pivot as it transitions to a clinical-stage obesity company with the upcoming IND filing for its oral MC4R agonist. This move effectively ends the R&D-only discount and starts a 30-day countdown to Phase 1. Despite persistent fears of dilution, major institutional holders like Janus Henderson and Driehaus are restricted by a 9.99% blocker provision, preventing them from dumping shares and ensuring the "smart money" stays positioned for the clinical transition..Which means thecurrent setup is a tinderbox because short interest represents over 13% of the tiny 1.7 million share float. Due to anemic daily volume from retail sellers ( ex. 6.5% drop today in last half hour on just 350 shares!)… it would now take~19 trading days for shorts to exit their positions... positive news on the IND filing could force a violent squeeze of historically 100-300% in a week of shorts cover.

1 · Reply

profitraider Apr. 1 at 11:47 PM

$RYTM Folks, the second leg down to form the double bottom hasn’t yet set in… And, if that fails, it’s game over!

1 · Reply

Atrain1189 Apr. 1 at 5:42 PM

$RYTM have a feeling my April 17 $100-105 calls will go worthless then it will moon shortly after

1 · Reply

Reneejordan001 Apr. 1 at 3:34 PM

$RYTM Anyone think it's Lilly that's interested?

2 · Reply

profitraider Apr. 1 at 12:47 AM

$RYTM Not Good… overall trend is downward… more pain to come!

0 · Reply

Fantastiqo Apr. 1 at 12:18 AM

$RYTM watching for tomorrow

0 · Reply

Rhythm Pharmaceuticals Announces Changes to Board of Directors

Mar 26, 2026, 9:01 AM EDT - 10 days ago

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment

Mar 20, 2026, 12:58 PM EDT - 16 days ago

PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide)

Mar 20, 2026, 3:32 AM EDT - 16 days ago

Rhythm Pharmaceuticals, Inc. (RYTM) Discusses FDA Approval of IMCIVREE for Acquired Hypothalamic Obesity Transcript

Mar 19, 2026, 6:30 PM EDT - 16 days ago

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

Mar 17, 2026, 2:02 AM EDT - 19 days ago

Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Topline Results and Insights from Phase 3 EMANATE Trial Transcript

Mar 16, 2026, 4:07 PM EDT - 19 days ago

Rhythm Pharma's obesity drug fails to meet main goal in late-stage trial

Mar 16, 2026, 4:01 PM EDT - 19 days ago

Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial

Mar 16, 2026, 7:30 AM EDT - 20 days ago

Rhythm Pharmaceuticals Q4 Beat Sets Stage For March 20th PDUFA Decision

Mar 1, 2026, 12:30 PM EST - 5 weeks ago

Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity

Feb 26, 2026, 3:08 PM EST - 5 weeks ago

Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2025 Earnings Call Transcript

Feb 26, 2026, 7:00 AM EST - 5 weeks ago

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

Feb 19, 2026, 12:42 PM EST - 6 weeks ago

Rhythm Pharmaceuticals Is Well-Positioned, Analyst Says Could Capture Big Share Of Rare Obesity Market

Feb 17, 2026, 8:00 AM EST - 6 weeks ago

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026

Feb 5, 2026, 8:00 AM EST - 2 months ago

Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit

Jan 9, 2026, 8:00 AM EST - 3 months ago

Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones

Dec 11, 2025, 4:28 PM EST - 4 months ago

Rhythm: PWS Signal, HO Speed Bump, And The Case For A Rare-Obesity Blockbuster

Dec 11, 2025, 3:52 PM EST - 4 months ago

Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Preliminary Phase II Data of Setmelanotide in Prader-Willi Syndrome and Next Steps Transcript

Dec 11, 2025, 1:17 PM EST - 4 months ago

Rhythm Pharma Strikes Chord As Early PWS Trial Results Show Promise

Dec 11, 2025, 7:30 AM EST - 4 months ago

Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome

Dec 10, 2025, 4:01 PM EST - 4 months ago

Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome

Nov 25, 2025, 5:34 PM EST - 4 months ago

Rhythm: Maintaining Strong Buy On Acquired Hypothalamic Obesity Drug Progress

Nov 10, 2025, 7:00 AM EST - 5 months ago

Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025

Nov 7, 2025, 7:30 AM EST - 5 months ago

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

Nov 5, 2025, 4:01 PM EST - 5 months ago

Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program

Nov 4, 2025, 8:06 PM EST - 5 months ago

Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 7:00 AM EST - 5 months ago

Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update

Oct 21, 2025, 4:01 PM EDT - 5 months ago

Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Sep 24, 2025, 5:07 PM EDT - 6 months ago

Rhythm Pharmaceuticals, Inc. - Special Call

Sep 9, 2025, 2:04 PM EDT - 7 months ago

Rhythm Pharmaceuticals, Inc. (RYTM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 27, 2025, 4:01 PM EDT - 7 months ago

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Aug 20, 2025, 4:01 PM EDT - 8 months ago

Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity

Aug 5, 2025, 5:26 PM EDT - 8 months ago

Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 7:00 AM EDT - 8 months ago

Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update

Jul 22, 2025, 4:01 PM EDT - 9 months ago

Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025

Jul 12, 2025, 6:00 PM EDT - 9 months ago

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

Jul 10, 2025, 3:39 PM EDT - 9 months ago

Rhythm: Oral Bivamelagon Data Signals Dominance In Hypothalamic Obesity Market

Jul 10, 2025, 6:21 AM EDT - 9 months ago

Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock

Jul 9, 2025, 4:16 PM EDT - 9 months ago

Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

Jul 9, 2025, 8:00 AM EDT - 9 months ago

Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity

Jul 8, 2025, 4:01 PM EDT - 9 months ago

Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity

Jun 30, 2025, 11:00 AM EDT - 9 months ago

Rhythm Pharmaceuticals: Rare Genetic Obesity Pioneer With Excellent Prospects

Jun 25, 2025, 8:00 AM EDT - 10 months ago

Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025

May 14, 2025, 8:00 AM EDT - 11 months ago

Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program

May 7, 2025, 3:21 PM EDT - 11 months ago

Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2025 Earnings Call Transcript

May 7, 2025, 7:00 AM EDT - 11 months ago

Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

Apr 8, 2025, 1:38 PM EDT - 1 year ago

Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder

Apr 7, 2025, 7:11 AM EDT - 1 year ago

Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in late-stage trial

Apr 7, 2025, 7:00 AM EDT - 1 year ago

Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity

Stonky_Mcprofitface Apr. 3 at 1:02 PM

$RYTM oh ok.

1 · Reply

Hognose Apr. 2 at 6:26 AM

$RYTM buyout candidate. About to get cheaper. Pickup in the 70s

1 · Reply

abcdzepeda Apr. 2 at 12:50 AM

$RYTM wow, we are trending right now!

1 · Reply

Tech442 Apr. 2 at 12:43 AM

$RYTM

0 · Reply

SportTrade Apr. 2 at 12:32 AM

1 · Reply

profitraider Apr. 1 at 11:47 PM

$RYTM Folks, the second leg down to form the double bottom hasn’t yet set in… And, if that fails, it’s game over!

1 · Reply

Atrain1189 Apr. 1 at 5:42 PM

$RYTM have a feeling my April 17 $100-105 calls will go worthless then it will moon shortly after

1 · Reply

Reneejordan001 Apr. 1 at 3:34 PM

$RYTM Anyone think it's Lilly that's interested?

2 · Reply

profitraider Apr. 1 at 12:47 AM

$RYTM Not Good… overall trend is downward… more pain to come!

0 · Reply

Fantastiqo Apr. 1 at 12:18 AM

$RYTM watching for tomorrow

0 · Reply

Atrain1189 Mar. 31 at 9:02 PM

$RYTM 2 mil volume and this move up today seems promising

0 · Reply

abcdzepeda Mar. 31 at 7:01 PM

$RYTM Dear lord, I thank you for all the families that will be helped by receiving IMCEVREE all over the world. I ask that you would release the shackles that have been holding back this stock from growing to the value that you and I both know that it possesses. I ask that you would give us patience and wisdom to know when is the right time to let go of the shares that we currently hold so that they would be a blessing to our family. I ask all this in the mighty and glorious name of. JESUS CHRIST!

1 · Reply

CharlieeMungerTWITS Mar. 31 at 4:08 PM

$RYTM brave money loaded that dip

1 · Reply

Stonky_Mcprofitface Mar. 31 at 3:38 PM

$RYTM So....$APLS with one billion in revenue and same gross margins as $RYTM gets taken out for $5.1 billion, double its value yesterday. Our market cap is already $5.7 billion. Any opinions on what the upside for RYTM is, if any? Is it already fairly priced?

3 · Reply

Stonky_Mcprofitface Mar. 31 at 2:16 PM

$RYTM You’re good at this.

1 · Reply

Atrain1189 Mar. 31 at 2:13 PM

$RYTM can we see $100+ in the coming weeks is the question?

0 · Reply

Big_Slick Mar. 31 at 2:12 PM

$RYTM

0 · Reply

Stonky_Mcprofitface Mar. 31 at 2:00 PM

$RYTM ok

0 · Reply

profitraider Mar. 30 at 5:59 PM

$RYTM Complete trash…

0 · Reply

Stonky_Mcprofitface Mar. 29 at 10:08 PM

$RYTM Losing 30% of your net with year to date is a lot easier to handle if the board of directors is going to hand you another 90,000 shares in a couple of weeks.

1 · Reply

Jud_yHam Mar. 28 at 3:47 PM

$RYTM biotech trend looks better when it stops giving back breakout candles

0 · Reply

profitraider Mar. 28 at 1:38 AM

$RYTM I told you people!

0 · Reply

Market Cap	5.89B
Revenue (ttm)	189.76M
Net Income (ttm)	-196.54M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-103.57%
Debt to Equity Ratio	0.00

Volume	546,400
Avg Vol	878,000
Day's Range	N/A - N/A
Shares Out	68.29M
Stochastic %K	71%
Beta	2.14
Analysts	Strong Sell
Price Target	$137.20